Search results

Order by most recent / most popular / relevance

Results: 1-10 of 391

Universities abroad experiment with no-fee licensing to drive biotech partnerships

Shook Hardy & Bacon LLP
-
Australia, Canada, European Union, United Kingdom, USA
-
May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

Putative class alleges pharma statements about new drug violated securities laws

Shook Hardy & Bacon LLP
-
USA
-
May 16 2013

Aveo Pharmaceuticals, Inc. and several of its executives have been targeted in a securities class action filed in a federal court in Massachusetts

EU Medicines Agency plans to appeal interim rulings on release of clinical trial data

Shook Hardy & Bacon LLP
-
European Union
-
May 16 2013

According to a news source, European Medicines Agency (EMA) Director Guido Rasi intends to appeal interim rulings recently issued by the European

NASDAQ Biotechnology Index surpasses all-time high in 1Q13

Shook Hardy & Bacon LLP
-
USA
-
May 16 2013

The NASDAQ Biotechnology Index reportedly rose in the first quarter of 2013 (1Q13) above levels last seen during the 2000 genomics bubble peakthe

Rapid biosimilar growth seen through 2023

Shook Hardy & Bacon LLP
-
Global
-
May 16 2013

British market-research firm Visiongain has forecast a $2.445-billion global market for biosimilars in 2013, a 20-percent increase over 2012, with

Congress advances pharma supply chain and animal-drug user-fee laws

Shook Hardy & Bacon LLP
-
USA
-
May 16 2013

The House Energy and Commerce Subcommittee on Health has reportedly approved draft legislation that would change the existing lot-level

Biotech receives $32.5 million for cancer research

Shook Hardy & Bacon LLP
-
USA
-
May 16 2013

Celator Pharmaceuticals, Inc., a Princeton, New Jersey-based company that develops cancer therapies, has raised $32.5 million in the final closing of

FDA argues to D.C. Circuit that stem cell treatment is a drug

Shook Hardy & Bacon LLP
-
USA
-
March 21 2013

Asserting that "FDA may lawfully regulate the creation of a new drug product even if it contains some of a patient's cells," the Food and Drug

French company prevails in dispute with FDA over drug-classification ruling

Shook Hardy & Bacon LLP
-
USA
-
October 3 2012

A federal court in the District of Columbia has determined that the Food and Drug Administration (FDA) erred when it classified a combination drug-device product as primarily a drug, thus subjecting its French manufacturer to more burdensome regulatory requirements

Cleave Biosciences secures $10 million to support cancer therapies

Shook Hardy & Bacon LLP
-
USA
-
April 18 2013

Cancer drug developer, Cleave Biosciences Inc., has secured $10 million in Series A financing from new investor New Enterprise Associates (NEA

next >

Search results

Universities abroad experiment with no-fee licensing to drive biotech partnerships

Putative class alleges pharma statements about new drug violated securities laws

EU Medicines Agency plans to appeal interim rulings on release of clinical trial data

NASDAQ Biotechnology Index surpasses all-time high in 1Q13

Rapid biosimilar growth seen through 2023

Congress advances pharma supply chain and animal-drug user-fee laws

Biotech receives $32.5 million for cancer research

FDA argues to D.C. Circuit that stem cell treatment is a drug

French company prevails in dispute with FDA over drug-classification ruling

Cleave Biosciences secures $10 million to support cancer therapies

Current Search

Suggested Facets

Author

Jurisdiction

Workarea